



**LIBERIA – YELLOW FEVER VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Liberia				
<b>2. Grant Number:</b> 0715-LBR-06b-X				
<b>3. Date of Decision Letter :</b> 17 October 2013				
<b>4. Date of the Partnership Framework Agreement:</b> 30 August 2013				
<b>5. Programme Title:</b> New Vaccine Support				
<b>6. Vaccine type:</b> Yellow Fever				
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED				
<b>8. Programme Duration<sup>1</sup>:</b> 2001-2015				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>				
	2001-2013	2014	2015	Total <sup>2</sup>
Programme Budget (US\$)	US\$1,363,808 <sup>3</sup>	US\$186,500	US\$227,000	US\$1,777,308
<b>10. Vaccine Introduction Grant:</b> N/A				
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>				
Type of supplies to be purchased with GAVI funds in each year	2001-2013	2014		
Number of Yellow Fever vaccines doses			169,600	
Number of AD syringes			125,100	
Number of re-constitution syringes			23,100	
Number of safety boxes			1,650	
Annual Amounts (US\$)	US\$1,363,808 <sup>5</sup>	US\$186,500		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.				
<b>13. Self-procurement:</b> N/A				

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that GAVI has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code: 0715-LBR-06b-X-C** - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	40,000	45,500
Value of vaccine doses (US\$)	US\$39,114	
Total Co-Financing Payments (US\$) (including freight)	US\$42,000	US\$49,500

**15. Operational support for campaigns: N/A**

	2014	2015
Grant amount (US\$)		

**16. Additional documents to be delivered for future disbursements: N/A**

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

**17. Financial Clarifications: N/A**

**18. Other conditions: N/A**

Signed by,

*Hind Khatib*

**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2014

**LIBERIA – PENTAVALENT VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Liberia				
<b>2. Grant Number:</b> 1115-LBR-04a-X				
<b>3. Date of Decision Letter :</b> 17 October 2013				
<b>4. Date of the Partnership Framework Agreement:</b> 30 August 2013				
<b>5. Programme Title:</b> New Vaccine Support				
<b>6. Vaccine type:</b> Pentavalent				
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
<b>8. Programme Duration<sup>6</sup>:</b> 2008-2015				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>				
	2008-2013	2014	2015	Total <sup>7</sup>
Programme Budget (US\$)	US\$8,460,627 <sup>8</sup>	US\$665,500	US\$940,500	US\$10,066,627
<b>10. Vaccine Introduction Grant:</b> N/A				
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>9</sup></b>				
Type of supplies to be purchased with GAVI funds in each year	2008-2013	2014		
Number of vaccines doses		314,600		
Number of AD syringes		358,300		
Number of safety boxes		4,000		
Annual Amounts (US\$)	US\$8,460,627	US\$665,500		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.				
<b>13. Self-procurement:</b> N/A				

<sup>6</sup> This is the entire duration of the programme.

<sup>7</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>8</sup> This is the consolidated amount for all previous years.

<sup>9</sup> This is the amount that GAVI has approved.

**14. Co-financing obligations: Reference code: 1115-LBR-04a-X-C** - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	34,100	48,400
Value of vaccine doses (US\$)	US\$66,316	
Total Co-Financing Payments (US\$) (including freight)	US\$70,000	US\$99,000

**15. Operational support for campaigns: N/A**

	2014	2015
Grant amount (US\$)		

**16. Additional documents to be delivered for future disbursements: N/A**

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

**17. Financial Clarifications: N/A**

**18. Other conditions: N/A**

Signed by,

*Hind K. Khatib*

**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2013

**LIBERIA – PNEUMOCOCCAL VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Liberia										
<b>2. Grant Number:</b> 1315-LBR-12c-X / 13-LBR-08c-Y										
<b>3. Date of Decision Letter :</b> 17 October 2013										
<b>4. Date of the Partnership Framework Agreement:</b> 30 August 2013										
<b>5. Programme Title:</b> New Vaccine Support										
<b>6. Vaccine type:</b> Pneumococcal										
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID										
<b>8. Programme Duration<sup>10</sup>:</b> 2014-2015										
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>										
<table border="1"> <thead> <tr> <th></th> <th>2014</th> <th>2015</th> <th>Total<sup>11</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td align="center">US\$2,988,500</td> <td align="center">US\$2,574,000</td> <td align="center">US\$5,562,500</td> </tr> </tbody> </table>		2014	2015	Total <sup>11</sup>	Programme Budget (US\$)	US\$2,988,500	US\$2,574,000	US\$5,562,500		
	2014	2015	Total <sup>11</sup>							
Programme Budget (US\$)	US\$2,988,500	US\$2,574,000	US\$5,562,500							
<b>10. Vaccine Introduction Grant:</b> US\$155,000 payable in 2014.										
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>12</sup></b>										
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with GAVI funds in each year</th> <th>2014</th> </tr> </thead> <tbody> <tr> <td>Number of Pneumococcal vaccines doses</td> <td align="center">567,300</td> </tr> <tr> <td>Number of AD syringes</td> <td align="center">635,600</td> </tr> <tr> <td>Number of safety boxes</td> <td align="center">7,075</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td align="center">US\$2,988,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with GAVI funds in each year	2014	Number of Pneumococcal vaccines doses	567,300	Number of AD syringes	635,600	Number of safety boxes	7,075	Annual Amounts (US\$)	US\$2,988,500
Type of supplies to be purchased with GAVI funds in each year	2014									
Number of Pneumococcal vaccines doses	567,300									
Number of AD syringes	635,600									
Number of safety boxes	7,075									
Annual Amounts (US\$)	US\$2,988,500									
<b>12. Procurement agency:</b> UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.										
<b>13. Self-procurement:</b> N/A										

<sup>10</sup> This is the entire duration of the programme.

<sup>11</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>12</sup> This is the amount that GAVI has approved.

**14. Co-financing obligations: Reference code: 1315-LBR-12c-X-C** - According to the Co-Financing Policy, the Country falls within the Low Income group. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	33,500	27,900
Value of vaccine doses (US\$)	US\$113,335	
Total Co-Financing Payments (US\$) (including freight)	US\$120,500	US\$99,000

**15. Operational support for campaigns: N/A**

	2014	2015
Grant amount (US\$)		

**16. Additional documents to be delivered for future disbursements: N/A**

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

**17. Clarifications: N/A**

**18. Other conditions: N/A**

Signed by,



**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2013

## LIBERIA – HEALTH SYSTEM STRENGTHENING SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b> Liberia
<b>2. Grant number:</b> 1214-LBR-10d-Y
<b>3. Date of Decision Letter :</b> 17 October 2013
<b>4. Date of the Partnership Framework Agreement:</b> 30 August 2013
<b>5. Programme Title:</b> Health Systems Strengthening (HSS)
<b>6. HSS terms:</b>  <p>The ultimate aim of HSS support is to ensure increased and sustained immunisation coverage through addressing health systems barriers in Country, as specified in:</p> <ul style="list-style-type: none"><li>• The relevant GAVI HSFP guidelines - please contact your CRO at <a href="mailto:periksson@gavialliance.org">periksson@gavialliance.org</a> for the guidelines.</li><li>• The relevant GAVI HSFP application form - please contact your CRO at <a href="mailto:periksson@gavialliance.org">periksson@gavialliance.org</a> for the application form.</li><li>• Country's approved grant proposal and any responses to the HSFP IRC's request for clarifications.</li></ul> <p>The HSS cash support shall be subject to GAVI's performance-based funding (PBF). Under this, the HSS support will be split into two payments: the programmed payment (based on implementation of the approved HSS grant) and the performance-based payment (based on improvements in immunisation outcomes). This means that in the first year, Country will receive 100% of the approved ceiling, or programme budget if different (the initial Annual Amount), as an upfront investment. After the first year, countries will receive 80% of the ceiling, or programme budget if different, based on implementation of the grant, and additional payments will be based on performance on immunisation outcome indicators. Note that countries whose total grant budget would fall below US\$3 million are exempt from this 80% rule.</p> <p>Country will have the opportunity to receive payments beyond the programme budget amount, for exceptional performance on the same immunisation outcomes. The maximum programmed payment plus performance payment may be up to 150% of the country ceiling.</p> <p>Given that Country's DTP3 coverage was <b>below 90%</b> in 2011 based on WHO/UNICEF estimates, Country will be rewarded for improving coverage with:</p> <ul style="list-style-type: none"><li>• \$30 per additional child immunised with DTP3, if DTP3 coverage increases and</li><li>• \$30 per additional child immunised with first dose of measles containing vaccine, if measles coverage increases.</li></ul> <p>The performance payments under the performance-based funding shall be used solely for activities to be implemented in the country's health sector.</p>
<b>7. Programme Duration</b> <sup>13</sup> : 2012-2014

<sup>13</sup> This is the entire duration of the programme.

**8. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement, if applicable):**

Note that with PBF, annual disbursements may be more or less than these endorsed amounts after the first year (see section 6 above).

	2012	2013	2014	Total <sup>14</sup>
Programme Budget (US\$)	US\$1,800,000	US\$1,440,000	US\$1,440,000	US\$4,680,000

**9. Indicative Annual Amounts (indicative) (subject to the terms of the Partnership Framework Agreement):**

The following disbursements are subject to the conditions set out in sections 6, 10, 11 and 12:

Programme Year	2012	2013	Total <sup>15</sup>
Annual Amount (SUS)	US\$1,800,000	US\$1,440,000	US\$3,240,000

**10. Financial Clarifications:** The Country shall provide the following clarifications to GAVI<sup>16</sup>: HSS audit report for the period ended June 30, 2012

If the bank account information most recently provided to GAVI has changed or changes prior to disbursement, the country will need to complete a bank account information form. Please contact [gavihss@gavialliance.org](mailto:gavihss@gavialliance.org) for the form.

**11. Documents to be delivered for future HSS cash disbursements:**

The Country shall deliver the following documents by the specified due dates as part of the conditions for approval and disbursements of the future Annual Amounts.

Reports, documents and other deliverables	Due dates
Annual Progress Reports (APRs). The APRs shall provide detail on the progress against milestones and targets against baseline data for indicators identified in the proposal, as well as the PBF indicators as listed in section 6 above. The APRs should also include a financial report on the use of GAVI support for HSS (which could include a joint pooled funding arrangement report, if appropriate) and use of performance payments, which have been endorsed by the Health Sector Coordination Committee (HSCC) or its equivalent.	15 May 2014 or as negotiated with Secretariat
Interim unaudited financial reports. Unless stated otherwise in the existing Aide Memoire between GAVI and the Country, the Country shall deliver interim unaudited financial reports on the HSS cash support no later than 45 days after the end of each 6-month reporting period (15 February for the period covering 1 July – 31 December and 15 August for the period covering 1 January – 30 June). Failure to submit timely reports may affect future funding.	15 February and 15 August
In order to receive a disbursement for the second approved year of the HSS grant (2014), Country shall provide GAVI with a request for disbursement, which shall include the most recent interim unaudited financial report.	As necessary

<sup>14</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>15</sup> This is the amount approved by GAVI.

<sup>16</sup> Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements



**12. Other conditions: The following terms and conditions shall apply to HSS support.**

Cash disbursed under HSS support may not be used to meet GAVI's requirements to co-finance vaccine purchases.

In case the Country wishes to alter the disbursement schedule over the course of the HSFP programme, this must be highlighted and justified in the APR and will be subject to GAVI approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the HSFP programme proposal. Utilisation of GAVI support stated in this letter will be subject to performance monitoring.

Signed by,



**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2013

